A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT01047319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-302 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.
Study identification
- NCT ID
- NCT01047319
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,047 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2010 (Actual)
- Primary completion
- Jun 30, 2017 (Actual)
- Completion
- Jun 30, 2017 (Actual)
- Last update posted
- Dec 9, 2021
2010 – 2017
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1267 | Homewood | Alabama | 35209 | — |
| Teva Investigational Site 1237 | Phoenix | Arizona | 85013 | — |
| Teva Investigational Site 1279 | Phoenix | Arizona | 85018 | — |
| Teva Investigational Site 1276 | Tucson | Arizona | 85704 | — |
| Teva Investigational Site 1272 | Pasadena | California | 91105 | — |
| Teva Investigational Site 1238 | Sacramento | California | 95817 | — |
| Teva Investigational Site 1280 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 1282 | Sarasota | Florida | 34233 | — |
| Teva Investigational Site 1275 | Atlanta | Georgia | 30309 | — |
| Teva Investigational Site 1250 | Peoria | Illinois | 61603 | — |
| Teva Investigational Site 1260 | Indianapolis | Indiana | 46202 | — |
| Teva Investigational Site 1263 | Shreveport | Louisiana | 71103 | — |
| Teva Investigational Site 1269 | Baltimore | Maryland | 21201 | — |
| Teva Investigational Site 1273 | Albany | New York | 12205 | — |
| Teva Investigational Site 1264 | Amherst | New York | 14226 | — |
| Teva Investigational Site 1261 | Akron | Ohio | 44320 | — |
| Teva Investigational Site 1245 | Cleveland | Ohio | 44195-5244 | — |
| Teva Investigational Site 1247 | Columbus | Ohio | 43221 | — |
| Teva Investigational Site 1244 | Portland | Oregon | 97225 | — |
| Teva Investigational Site 1281 | Nashville | Tennessee | 37205 | — |
| Teva Investigational Site 1270 | Roanoke | Virginia | 24018 | — |
| Teva Investigational Site 1253 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01047319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01047319 live on ClinicalTrials.gov.